Last Updated : April 4, 2024
Details
FilesProject Status:
Completed
Project Line:
Health Technology Review
Project Sub Line:
Technology Review
Project Number:
HC0053-000
The drug utilization study explored the characteristics of patients with chronic idiopathic urticaria (CIU) who were administered omalizumab, as well as the use of omalizumab for longer than 24 weeks in 4 Canadian provinces.
The incidence of omalizumab treatment episodes for CIU has increased since it was first recommended for listing on drug benefit plans for CIU. Most episodes of treatment in the 4 provinces exceeded 24 weeks, with many episodes exceeding 48 weeks. No clear demographic factors differentiating short-term and long-term recipients of these treatment episodes were identified. The results of this analysis included 4 Canadian provinces and may not necessarily be generalizable to other jurisdictions within Canada.
Files
Last Updated : April 4, 2024